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Introduction: The established neuroprotective property of the sex steroid precursor dehydroepiandrosterone-
sulfate (DHEAS) has not yet been investigated in the context of aneurysmal subarachnoid hemorrhage (aSAH). The
influence of DHEAS on inflammatory response resulting in modulation of interleukin 6 (IL-6) synthesis has been
shown. Here, we evaluate DHEAS serum levels after aSAH (day 0–14) and levels of IL-6 related to functional outcome at
discharge and at six months.
Methods: A complete data set (DHEAS and IL-6 serum levels for days 0, 1, 4, 7, 10 and 14 after aSAH) and outcome
assessment at discharge according to modified Rankin Scale score (mRS) was available for 53 patients of the initially
screened cohort (n = 109). Outcome assessment six months after aSAH was obtained from 41 patients. Logarithmized
levels of DHEAS and IL-6 were related to dichotomized functional outcome either assessed at discharge or at six
months. A mixed between-within subjects ANOVA was applied for statistical analysis (SPSS 21.0).
Results: DHEAS and IL-6 levels across time were related to functional outcome. Regarding outcome assessment at
discharge and at six months after aSAH, DHEAS levels (transformed to square root for statistical purposes) were
considerably higher in patients with favorable outcome (mRS 0–2) (p = .001; p = .020). Inversely, in patients with
favorable outcome either at discharge or six months after aSAH, lower IL-6 levels (logarithmized for statistical purposes)
were observed across time (both p < .001).
Conclusion: We provide new evidence that DHEAS is associated with protective properties resulting in improvement
of functional outcome after aSAH, possibly by influencing the inflammatory response after aSAH shown in the
decreasing IL-6 serum levels. But the results for outcome six months after SAH are limited due to a high drop-out rate.Introduction
Aneurysmal subarachnoid hemorrhage (aSAH) is a se-
vere condition. Despite a gradual decrease over the last
decades, case fatality still accounts for 40 % [1]. Patients
affected are younger (mean 52 years) than those struck
by ischemic stroke. Therefore, and due to a high rate of* Correspondence: ahoellig@ukaachen.de
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as well as the costs for society are enormous [2, 3].
There is evidence that hormonal influence, specifically
neuroprotective effects achieved by sex steroids, may al-
leviate the brain injury generated by aSAH [4–6]. While
the clinical finding that female sex is a risk factor for
aSAH consolidated this hypothesis, it has only been
demonstrated in older cohorts (>50 years) [7–9]. How-
ever, the data are still conflicting with no definite con-
sensus on the possible influence and mechanism of sex
steroid action after aSAH [10].icle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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fate ester of dehydroepiandrosterone (DHEA); both are
multifunctional steroid hormones and precursors of sex
steroids constituting the most abundant human steroid
hormones [11]. DHEAS easily crosses the blood brain
barrier [12]. Within the central nervous system, it displays
various effects contributing to neuroprotection, such as
anti-inflammatory, pro-survival and anti-glucocorticoid
properties [11]. Experimental and clinical studies have
repeatedly reported the neuroprotective properties of
DHEAS [13–16].
DHEAS also influences neuroinflammation: synthesis
of IL-6, a major cytokine involved in neuroinflammation
[17], may be inhibited by DHEAS [18] and a negative
correlation of DHEAS with IL-6 has been shown in vitro
[19]. In a physiological state, IL-6 plays a role in neuro-
poiesis and neurogenesis [20, 21], whereas under patho-
physiological conditions, it is one of the major stimuli of
neuroinflammatory response [17, 22–24]. With respect to
aSAH, there is evidence that higher early serum IL-6 levels
predict an unfavorable outcome most probably by contrib-
uting to the early inflammatory response after aSAH as
part of early brain injury [25].
Given the neuroprotective effects of DHEAS and its
interaction with IL-6, this linkage of the neuroendocrine
with the neuroinflammatory system may exert neuropro-
tective properties via DHEAS-mediated attenuation of
the early inflammatory response. Thus, we aimed to as-
sess the role of DHEAS and its relation to IL-6 after
aSAH. By analyzing DHEAS and IL-6 serum levels
across time and relating these results to functional out-
come (determined by modified Rankin scale score (mRs)
at discharge and 6 months after aSAH), we aimed to elu-
cidate the potential beneficial effects of DHEAS and its
relationship with neuroinflammation.
Methods
The prospective study was approved by the local eth-
ics committee (Ethikkommission an der Medizinischen
Fakultät der Rheinischen Friedrich-Wilhelms-Universität
Bonn, Germany; EK 199/08). Written informed consent
was obtained from patients or legal representatives. With-
in a 21-month period (February 2009 to November 2010)
109 consecutive patients with a proven aSAH were
screened for eligibility. Patients were not eligible if they
were younger than 18 years, enrolled in other clinical tri-
als, admitted more than 12 h after onset or if informed
consent could not be obtained. In total, 81 patients (74 %)
were included. At admission, demographic data, severity
score for aSAH according to the World Federation of
Neurosurgical Societies (WFNS) classification and time
span to clinical ictus were assessed. Treatment of pa-
tients was carried out according to standardized guide-
lines [26]. Serum levels of DHEAS (lower limit of detection(LOD) 150 ng/ml) and IL-6 (LOD 2 pg/ml) were mea-
sured directly at admission and on days 1, 4, 7, 10 and
14 after aSAH (always in the morning) in line with rou-
tine diagnostics at the Department of Clinical Chemistry
and Clinical Pharmacology, University of Bonn. Samples
were centrifuged for 10 minutes at 2000 g prior to
processing.
At discharge and 6 months thereafter, functional out-
come according to the mRS was determined. For statis-
tical analysis, the mRS was dichotomized (mRS 0–2 =
favorable, mRS 3–6 = unfavorable). Scores according to
the WFNS grading scale were also dichotomized with
WFNS 1–3 defined as mild hemorrhage and WFNS 4
and 5 defined as severe hemorrhage. Furthermore, pa-
tient age was dichotomized to assess age-dependent dif-
ferences (age <55 years vs >55 years).
Normality of the distribution was tested by the
Kolmogorov–Smirnov test. Data were checked for out-
liers, and the data for one patient had to be removed
(100-fold increase of IL-6 levels at day 1 compared to
other results from the same patient). For descriptive ana-
lysis, mean, minimum and maximum values, standard de-
viation (SD) and 95 % confidence interval (95 % CI) were
calculated. Graphs show mean values and 95 % CI. For
skewed data, the mixed between-within subjects analysis
of variance (ANOVA) data were tested for normal dis-
tribution. Sphericity assumption was checked; violation
(significant Mauchly test) was compensated for using
Greenhouse-Geisser or Huyn-Feldt corrected degrees of
freedom as alternative requirements for appropriate ana-
lysis. Data were transformed (using logarithm (log) or
square root (sqrt)) to ensure homogeneity of variances
and sphericity (or its respective alternative requirements).
Subgroup analyses (for gender, age and WFNS score) were
only performed related to outcome at discharge, due to
the small sample size. A p-value less than 0.05 was
regarded to be statistically significant. Statistical analysis
was performed using IBM SPSS 21.0 software. All graphs
were drawn using GraphPad Prism 6.
Results
Baseline characteristics
At admission, samples were available for analysis from
76 of the 81 patients (94 %) initially included (Fig. 1).
Data for one patient had to be excluded prior to analysis
due to an outlier value. Baseline data for the remaining
75 patients are shown in Table 1. Due to patient deaths
(total n = 10; 13 % of the patients initially included) or
incomplete data (n = 12; 16 % of the patients initially in-
cluded) the sample size decreased over time leaving data
for 53 of 81 patients (65 %) available for analysis on day
14. Complete datasets (measured values for day 0–14)
for outcome according to mRS 6 months after aSAH
were available for 41 patients (51 %).
Fig. 1 Flowchart of patients enrolled. Diagram of patient enrolment and subsequent data analysis. aSAH Aneurysmal subarachnoid hemorrhage
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DHEAS serum levels were assessed from day 0 to day 14
of the inpatient stay (always in the morning) (Table 2;
Fig. 2).
As DHEAS levels are dependent on gender and age,
additional analysis of data for each subgroup was per-
formed: DHEAS levels over time are shown in relation
to gender (Additional file 1: Figure S1A) and to age (<55
years vs >55 years) (Additional file 1: Figure S1B). Mixed
ANOVA with gender as a between-subjects effect did
not show a significant difference in DHEAS levels (ex-
pressed as sqrtDHEAS) (F (1, 50) = .155; p = .695). How-
ever, with age as the between-subjects effect there was a
significant difference between the time course of DHEAS
levels (expressed as its sqrt) (F (1, 50) = 4.5; p = .039).Table 1 Baseline characteristics
Baseline characteristics
Number of patients n = 75
Sex (female) n = 49 (65 %)
Mean age +/−SD (yrs) 53 +/−13
WFNS:
WFNS 1 n = 22 (29 %)
WFNS 2 n = 13 (17 %)
WFNS 3 n = 5 (7 %)
WFNS 4 n = 14 (19 %)
WFNS 5 n = 21 (28 %)
Aneurysm treatment:
Endovascular treatment n = 52 (69 %)
Surgical treatment n = 23 (31 %)
WFNS World Federation of Neurosurgical Societies scoreThe clinical time course after aSAH is influenced con-
siderably by the severity of injury. Therefore, the time
course of DHEAS levels were analyzed related to severity
of hemorrhage. As a surrogate parameter classification
according to the WFNS grading scale was used (WFNS
1–3 = mild; WFNS 4, 5 = severe). The time course of
DHEAS levels did not differ in relation to the severity
of injury (Additional file 1: Figure S1C) (F (1, 50) = 2.79;
p = .101).DHEAS levels related to outcome at discharge and
6 months after aSAH
To evaluate the possibility of correlation of DHEAS
levels on outcome, DHEAS serum levels were analyzed
related to patients’ outcome at discharge (expressed via
dichotomized mRS) (Table 3, Fig. 2a). Overall, higher
serum DHEAS levels were found in the subgroup with
favorable outcome at discharge.
To additionally assess long-term effects, the correl-
ation between early DHEAS levels and levels at 6-monthTable 2 DHEAS levels during the inpatient stay
Minimum Maximum Mean SD 95 % CI Number
DHEAS day 0 <150 5260 1197 941 884, 1367 75
DHEAS day 1 <150 4460 961 850 671, 1105 73
DHEAS day 4 <150 2840 554 593 363, 675 68
DHEAS day 7 <150 3780 546 670 356, 676 66
DHEAS day 10 <150 5770 639 968 370, 792 62
DHEAS day 14 <150 2560 515 543 360, 666 53
Time course of dehydroepiandrosterone-sulfate (DHEAS) levels (ng/ml) during
the inpatient stay (up to day 14 after aneurysmal subarachnoid hemorrhage.
Number number of patients analyzed
Fig. 2 Time course of dehydroepiandrosterone-sulfate (DHEAS) and IL-6 related to outcome at discharge. Time course of DHEAS (a) and IL-6
(b) serum levels (mean + 95 % CI) related to dichotomized outcome at discharge (according to the modified Rankin scale score (mRS)
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14 were also found to be related to outcome 6 months
after aSAH (expressed as the dichotomized mRS; Table 4;
Fig. 2b). However, a high drop-out rate hampers the in-
terpretation of the long-term results.
To objectify this observation, mixed between-within
subjects ANOVA was conducted to compare the time
course of DHEAS levels with respect to outcome (ex-
pressed as dichotomized mRS). Due to skewed data and
to fulfil the demands of sphericity and homogeneity of
variances, DHEAS levels were expressed as its sqrt. TheTable 3 DHEAS levels during the inpatient stay according to
functional outcome at discharge (dichotomized modified Rankin
Scale score)
Minimum Maximum Mean SD 95 % CI Number
DHEAS day 0
Favorable <150 5260 1431 1077 1081, 1782 38
Unfavorable <150 2370 955 730 712, 1199 37
DHEAS day 1
Favorable <150 4460 1132 989 802, 1462 37
Unfavorable <150 2740 785 646 566, 1004 36
DHEAS day 4
Favorable <150 2840 710 662 486, 934 36
Unfavorable <150 1700 223 453 215, 542 32
DHEAS day 7
Favorable <150 3780 781 796 507, 1054 35
Unfavorable <150 1110 282 343 156, 407 31
DHEAS day 10
Favorable <150 5770 961 1202 542, 1380 34
Unfavorable <150 937 247 245 152, 342 28
DHEAS day 14
Favorable <150 2560 634 602 405, 863 29
Unfavorable <150 1520 371 430 189, 553 24
Dehydroepiandrosterone-sulfate (DHEAS) levels (ng/ml) during the acute stage
of disease according to dichotomized (Favorable vs Unfavorable modified
Rankin Scale score) outcome at discharge. Number number of cases analyzedbetween-subjects effect (outcome at discharge) was strongly
significant (F (1, 50) = 12.98; p <.0005) with higher
sqrtDHEAS levels over the observation period in patients
with favorable outcome at discharge. Although across
time the serum DHEAS levels changed significantly
(F (4.36, 218.19) = 21.81; p <.0005), this pattern of change
did not differ between the two outcome groups (interaction
of DHEAS across time with outcome, F (4.36, 218.19) =
1.29; p = .272). We demonstrated a different time course of
DHEAS levels over time for patients with a favorable out-
come at discharge compared to those with an unfavorableTable 4 DHEAS levels during the inpatient stay according to
functional outcome 6 months after aneurysmal subarachnoid
hemorrhage (dichotomized modified Rankin scale score)
Minimum Maximum Mean SD 95 % CI Number
DHEAS day 0
Favorable <150 5260 1411 1161 1000, 1823 33
Unfavorable <150 2310 1052 678 766, 1338 24
DHEAS day 1
Favorable <150 4460 1135 1035 768, 1502 33
Unfavorable <150 2740 820 609 563, 1077 24
DHEAS day 4
Favorable <150 2840 699 700 451, 948 33
Unfavorable <150 1700 515 497 283, 748 20
DHEAS day 7
Favorable <150 3780 770 838 467, 1072 32
Unfavorable <150 1110 339 324 187, 491 20
DHEAS day 10
Favorable 155 5770 982 1251 523, 1441 31
Unfavorable <150 776 255 249 127, 383 17
DHEAS day 14
Favorable <150 2560 669 604 435, 903 28
Unfavorable <150 1090 359 342 153, 566 13
Dehydroepiandrosterone-sulfate (DHEAS) levels (ng/ml) during acute stage of
disease according to dichotomized (Favorable vs Unfavorable) outcome 6 months
after aneurysmal subarachnoid hemorrhage. Number number of cases analyzed
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with age, we performed subgroup analysis by patient age
(<55 years vs >55 years) (Additional file 2: Figure S2): the
time course of DHEAS levels (sqrtDHEAS) in relation to
outcome at discharge was significantly different in both
groups, but this difference was more pronounced in the
younger patients (<55 years, F (1, 27) = 8.16; p = .008; >55
years, F (1, 20) = 4.63; p = .044). However, the sample size
of the subgroups was very small.
Mixed ANOVA was also conducted for dichotomized
outcome assessed 6 months after aSAH. Again, on
analysis of the between-subjects effect (outcome 6
months after aSAH) there was a significant difference
in sqrtDHEAS levels (F (1, 38) = 5.89; p = .020) be-
tween the two outcome groups. As expected from the
analysis of outcome at discharge, longitudinal change in
serum DHEAS levels did not differ between the two out-
come groups (F (5, 190) = 1.39; p = .229), but sqrtDHEAS
serum levels changed significantly over time (F (5, 190) =
13.7; p <.0005). Subgroup analysis of the outcome 6
months after aSAH was not performed due to the small
sample size.
These results suggest a distinct time course of DHEAS
levels in patients with a favorable outcome compared to
those with an unfavorable outcome. Specifically, there is
evidence for higher DHEAS serum levels across time in
patients with a favorable outcome at least when assessed
at discharge.
Time course of serum IL-6 levels
Serum IL-6 levels were also measured over the whole
observation period (days 0–14, always in the morning)
(Table 5, Fig. 3).
Analogous to DHEAS, serum IL-6 levels across time
(Table 5, Fig. 3) were also related to outcome according
to dichotomized mRS at discharge and 6 months after
aSAH (Tables 6 and 7, Fig. 3b).
As the severity of injury also might influence IL-6 se-
cretion, the time course of serum IL-6 levels was ana-
lyzed in relation to the dichotomized WFNS score.
Especially during the early time course, serum IL-6 levels
differed visibly (Additional file 3: Figure S3). Objectified byTable 5 IL-6 levels during the inpatient stay
Minimum Maximum Mean SD 95 % CI Number
IL-6 day 0 <2 529 24 63 10, 39 75
IL-6 day 1 <2 194 26 33 19, 34 73
IL-6 day 4 <2 878 37 113 10, 65 68
IL-6 day 7 <2 413 30 61 15, 45 66
IL-6 day 10 <2 241 20 36 11, 29 62
IL-6 day 14 <2 905 33 124 −1, 67 53
Time course of IL-6 levels (pg/ml) during the inpatient stay (up to day 14 after
aneurysmal subarachnoid hemorrhage). Number number of cases analyzedmixed ANOVA, serum IL-6 levels (expressed as logIL-6)
varied over time in relation to the WFNS score (F (1, 43) =
8.62; p = .005).
Corresponding to the DHEAS analysis, mixed between-
within subjects ANOVA was conducted to evaluate IL-6
serum levels across time in relation to outcome. Due to
skewed data, serum logIL-6 levels were calculated prior to
analysis. Across time, the logIL-6 levels did not change
significantly (F (3.97, 170.84) = 1.94; p = .116). Comparing
the two outcome groups at discharge (favorable vs un-
favorable) the pattern of logIL-6 levels did not differ be-
tween the groups (F (3.97, 170.84) = .886; p = .473). Of
note, the between-within subject effect indicating different
time courses of logIl-6 levels in relation to the dichoto-
mized outcome score (favorable vs unfavorable) was
strongly significant (F (1, 43) = 32.08; p < .0005). Thus,
these results suggest a difference in IL-6 levels, with
higher IL-6 levels across time in the group with an un-
favorable outcome.
In the subgroups with WFNS 1–3 vs WFNS 4, 5, there
was a significant difference in the time course of serum
IL-6 (logIL-6) levels in relation to outcome at discharge
in both subgroups (mild hemorrhage WFNS 1–3, F (1,
20) = 5.08; p = .036; severe hemorrhage WFNS 4, 5, F (1,
21) = 16.85; p = .001), but again the sample size was small
(Additional file 4: Figure S4).
For outcome assessed 6 months after aSAH, no signifi-
cant main effects were noted for time (F (4.68, 154.4) =
.948; p = .448) or interaction of time and outcome after
6 months (F (4.68, 154.4) = .878; p = .492). Again, the
main effect comparing the two outcome groups was sig-
nificant (F (1, 33) = 17.15; p <.0005) suggesting a differ-
ence between the outcome groups in IL-6 levels over
time, with higher IL-6 levels in the group with an un-
favorable long-term outcome.
Discussion
A favorable outcome at discharge and 6 months after
aSAH was related to higher DHEAS serum levels during
the acute treatment period after aSAH. Inversely, serum
levels of IL-6 were considerably lower in patients with a
favorable outcome. Thus, we might assume that there is
a functional link between the anti-inflammatory proper-
ties of DHEAS and the less pronounced inflammatory
reaction in terms of IL-6 expression after aSAH, result-
ing in an improved outcome.
DHEAS has demonstrated multiple neuroprotective ef-
fects [14–16, 27]. Multiple mechanisms of action have been
suggested, such as modulation of Gamma-aminobutyric-
acid-A(GABAA)-receptor signaling [15, 28], inhibition of
N-methyl-D-aspartate (NMDA)-receptor function, sigma
receptor or glutamate receptor signaling [12, 29]. Gen-
omic and non-genomic signaling via direct interaction
with postsynaptic receptors has been demonstrated [30].
Fig. 3 Time course of dehydroepiandrosterone-sulfate (DHEAS) and IL-6 related to outcome 6 months after aneurysmal subarachnoid hemorrhage
(aSAH). Time course of DHEAS (a) and IL-6 (b) serum levels (mean + 95 % CI) related to dichotomized outcome 6 months after aSAH (according
to the modified Rankin scale score (mRS))
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seems to be versatile, resulting in multiple effects, such as
anti-inflammatory action. In fact, sex hormones modulate
the immune system [31, 32]. An influence on IL-6 synthesis
has been demonstrated specifically for DHEAS [33, 34].
Apart from physiological derangements (such as elevation
of intracranial pressure and reduction of cerebral blood
flow), oxidative and metabolic disturbances, pathological
acute vascular reactions, ionic changes etc., inflammatoryTable 6 IL-6 levels during the inpatient stay according to
functional outcome at discharge (dichotomized modified Rankin
scale score)
Minimum Maximum Mean SD 95 % CI Number
IL-6 day 0
Favorable <2 109 12 20 6, 18 38
Unfavorable <2 529 37 86 9, 66 37
IL-6 day 1
Favorable <2 122 18 22 11, 25 37
Unfavorable 3 194 35 40 21, 49 35
IL-6 day 4
Favorable <2 175 14 30 4, 25 36
Unfavorable <2 878 63 160 5, 120 32
IL-6 day 7
Favorable <2 53 12 14 7, 16 35
Unfavorable <2 413 51 84 20, 82 31
IL-6 day 10
Favorable <2 33 8 8 5, 11 35
Unfavorable 3 241 34 50 15, 53 28
IL-6 day 14
Favorable <2 30 6 6 4, 9 29
Unfavorable 2 905 65 181 −12, 141 24
IL-6 levels (pg/ml) during the acute stage of disease according to dichotomized
(Favorable vs Unfavorable) outcome at discharge. Number number of cases
analyzedreactions arise early after aSAH [35, 36]. Currently, it is
assumed that these pathological mechanisms contribute
largely to the development of secondary injuries and, fi-
nally, to the limited chance for favorable outcome after
aSAH. Lower IL-6 levels were shown to be related to an
improved outcome [25]. Elevated DHEAS and reduced
IL-6 serum levels measured in patients with a favorable
outcome possibly indicate a protective hormonal and in-
flammatory pattern. This effect may be assumed to be theTable 7 IL-6 levels during the inpatient stay according to
functional outcome 6 months after aneurysmal subarachnoid
hemorrhage (dichotomized modified Rankin scale score)
Minimum Maximum Mean SD 95 % CI Number
IL-6 day 0
Favorable 2 109 14 21 7, −22 33
Unfavorable <2 529 46 16 1, 90 24
IL-6 day 1
Favorable <2 122 20 23 11, 28 32
Unfavorable 3 194 34 43 16, 53 24
IL-6 day 4
Favorable <2 315 19 55 −1, 38 33
Unfavorable 5 129 29 31 14, 43 20
IL-6 day 7
Favorable <2 60 12 13 7, 17 32
Unfavorable <2 413 61 101 14, 109 20
IL-6 day 10
Favorable <2 33 9 9 6, 12 32
Unfavorable <2 241 31 56 2, 59 17
IL-6 day 14
Favorable <2 42 9 10 5, 12 28
Unfavorable 6 75 27 22 13, 40 13
IL-6 levels (pg/ml) during the acute stage of disease according to dichotomized
(Favorable vs Unfavorable) outcome 6 months after aneurysmal subarachnoid
hemorrhage. Number number of cases analyzed
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ing to decreased IL-6 synthesis, thus confirming the well-
known link between the neuroendocrine and immune net-
work [31].
Additionally, decreased DHEA(S) levels have been re-
lated to the risk of cardiovascular diseases, reducing the
incidence of cardiovascular pathologies [13, 37]. Vaso-
protective properties inhibiting remodeling after vascular
injury have been observed in experimental studies [38].
However, the results of published clinical studies are
conflicting [39]. Despite these uncertainties, neuroster-
oids are still regarded as promising therapeutic agents
because there is substantial experimental evidence for
beneficial cardiovascular effects due to anti-inflammatory,
vasorelaxant and anti-remodeling properties [40, 41]. In a
model for vascular remodeling, DHEA alleviates oxida-
tive stress and inflammation with decreased IL-6 mRNA
expression via inhibition of p38 mitogen-activated pro-
tein kinase/nuclear factor κB (p38 MAPK/NF-κB) [38].
These vasoprotective properties, which ameliorate oxida-
tive and inflammatory stress after vascular lesions, may
also contribute to the suspected beneficial effect of
higher DHEAS serum levels after aSAH. Thus, an anti-
inflammatory reaction by DHEAS resulting in IL-6 syn-
thesis could also occur locally, i.e. directly at the affected
vessels.
Limitations of this study arise from its relatively small
and inhomogeneous cohort (both sexes, wide age range,
aSAH graded WFNS 1–5). Therefore, standard varia-
tions are considerably high. Furthermore, there was a
substantial drop-out rate in relation to the outcome as-
sessment 6 months after aSAH. Patients lost to follow
up are most likely those with an unfavorable outcome.
Therefore, our long-term results are biased by the re-
sponse rate 6 months after aSAH and are insufficient to
assess the relationship between long-term outcome and
the time course of DHEAS levels. More reliable results
may be obtained by a follow-up study with a larger and
more homogeneous cohort as well as a tighter follow-up
schedule.
Only DHEAS but not DHEA or androstenedione
(ASD) was assessed. DHEAS forms the pool for DHEA
and ASD. Furthermore, conversion of downstream ster-
oid hormones is based on the presence of DHEAS.
Therefore, DHEAS levels reflect the reservoir for further
synthesis. Another advantage of choosing DHEAS as a
marker for the presence of neuroactive steroid is its sta-
bility and feasibility of detection. Thus, as already shown
by various previous studies, we favor the approach of de-
termining DHEAS as a surrogate marker for neuroactive
steroids.
Outcome assessed according to the mRS only roughly
reflects the neurological and functional status of the pa-
tients. Moreover, outcome scores were dichotomized foranalysis. Thus, subtle discrete changes in outcome are
not detectable by this approach. Age and gender influence
DHEAS levels: subgroup analyses were performed to rule
out major flaws and even if the age-dependent subgroups
are examined, DHEAS levels over time differed in relation
to outcome at discharge. However, the sample size for sub-
group analysis was too small to make a firm conclusion.
The same applies to IL-6 serum levels: an increase in
IL-6, especially when measured in serum, may reflect an
unspecific response to stress and cytokine production,
may be related more to a global inflammatory reaction
than to a specific pathophysiological mechanism in-
volved in early brain injury after aSAH. Nevertheless, in
line with our initial hypothesis, subgroup analysis ac-
cording to WFNS score also revealed a significantly dif-
ferent time course for serum IL-6 levels in patients with
an unfavorable outcome compared to those with a favor-
able outcome. Alhough serum IL-6 probably does not
reflect the extent of neuroinflammation after aSAH in
detail, it may serve as an easily accessible (though unspe-
cific) surrogate parameter for global inflammatory burden
after aSAH. However, regardless of its final interpretation,
use of serum IL-6 instead of cerebral (measured by micro-
dialysis) or cerebrospinal fluid IL-6 is indispensable in re-
lating the results to DHEAS levels, which have also been
measured in serum.
The time course of DHEAS and IL-6 is difficult to in-
terpret. There is a distinct pattern for IL-6 with a peak
at day 4 followed by a slow decrease. By contrast,
DHEAS dropped towards day 4 and roughly remained at
the current level. Though the time course of IL-6 and
that of DHEAS behave conversely, the mechanism be-
hind these patterns remains unidentified. Occurrence of
both delayed cerebral ischemia (DCI) and death during
the inpatient time course in our patient group peaked
after day 4 (DCI day 7, death day 10). Even if regarded
as an early biomarker peak, the IL-6 levels at day 4
followed by a decrease are not plausibly explained by the
occurrence of DCI at day 7, neither by death at day 10.
Finally, mostly descriptive data are presented. Based on
the complexity of interactions, skewed data, confounders
and the dynamic acquisition of data, the data analysis
and interpretation is difficult and error-prone when
evaluating a small and inhomogeneous cohort.Conclusion
Taken together, we present for the first time the serum
profiles of DHEAS and IL-6 during the acute stage after
aSAH and their relationship to outcome. There is evi-
dence that DHEAS exerts protective effects with im-
provement of functional outcome after aSAH, possibly
by influencing the inflammatory response after aSAH by
decreasing IL-6 serum levels. Further studies with a
Höllig et al. Critical Care  (2015) 19:231 Page 8 of 9larger sample size are necessary to better adjust for con-
founders such as age, gender or smoking status.
Key messages
 Higher DHEAS levels may be beneficial to
functional outcome after aSAH.
 The possible action of mechanism may be a
modulation of the inflammatory response after
aSAH by DHEAS, resulting in decreased IL-6 serum
levels.
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